Remlifanserin
Remlifanserin ( ; developmental code name ACP-204) is a selective serotonin 5-HT 2A receptor inverse agonist which is under development for the treatment of Alzheimer's disease psychosis.
≈ 2 min read
Remlifanserin. encyclopegia.org, snapshot enwiki-001370299373. /a/remlifanserin
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Remlifanserin ( ; developmental code name ACP-204) is a selective serotonin 5-HT 2A receptor inverse agonist which is under development for the treatment of Alzheimer's disease psychosis. It is taken by mouth. The drug is an improved follow-up compound to the earlier drug pimavanserin (Nuplaizid; ACP-103).
It is more potent and selective than pimavanserin as a serotonin 5-HT 2A receptor inverse agonist. Remlifanserin shows 32- to 123-fold selectivity for antagonism and inverse agonism of the serotonin 5-HT 2A receptor over the serotonin 5-HT 2C receptor depending on the bioassay. For comparison, pimavanserin's selectivity was 8- to 37-fold depending on the assay.
Remlifanserin shows very low affinity for the serotonin 5-HT 2B receptor compared to the serotonin 5-HT 2A and 5-HT 2C receptors. It is expected to have less hERG inhibition and QT prolongation than pimavanserin.
The drug blocks the head-twitch response induced by the serotonergic psychedelic DOI and the hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) in rodents. It has a several-fold shorter half-life than pimavanserin (17.5–19.8 hours vs. 57 hours, respectively). Remlifanserin is under development by Acadia Pharmaceuticals.
As of January 2025, it is in phase 3 clinical trials. Some of its clinicaltrials.gov identifier(s) (nct number) are NCT06159673, NCT07029581, NCT06194799, NCT07095465.
See also
Serotonin 5-HT 2A receptor antagonist List of investigational antipsychotics List of investigational Parkinson's disease drugs
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370299373 under CC BY-SA 4.0; modifications have been made.